{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T14:27:56Z","timestamp":1769092076233,"version":"3.49.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,5,18]],"date-time":"2016-05-18T00:00:00Z","timestamp":1463529600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"National Institute of Allergy and Infectious Diseases (NIH), Bethesda, United States"},{"name":"Institute of Liver and biliary Sciences, New Delhi, India"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1007\/s12072-016-9733-6","type":"journal-article","created":{"date-parts":[[2016,5,18]],"date-time":"2016-05-18T08:21:49Z","timestamp":1463559709000},"page":"937-946","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Elevated hepatic lipid and interferon stimulated gene expression in HCV GT3 patients relative to non-alcoholic steatohepatitis"],"prefix":"10.1007","volume":"10","author":[{"given":"Shikha","family":"Shrivastava","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric G.","family":"Meissner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Funk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seerat","family":"Poonia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virender","family":"Shokeen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arun","family":"Thakur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhawna","family":"Poonia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiv Kumar","family":"Sarin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nirupma","family":"Trehanpati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shyamasundaran","family":"Kottilil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,5,18]]},"reference":[{"key":"9733_CR1","doi-asserted-by":"crossref","unstructured":"MohdHanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age specific antibody to HCV seroprevalence. Hepatology 2013;57:1333\u20131342","DOI":"10.1002\/hep.26141"},{"key":"9733_CR2","doi-asserted-by":"crossref","unstructured":"Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006;44:865\u2013873","DOI":"10.1002\/hep.21327"},{"key":"9733_CR3","doi-asserted-by":"crossref","unstructured":"Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995;22:1714\u20131719","DOI":"10.1002\/hep.1840220616"},{"key":"9733_CR4","doi-asserted-by":"crossref","unstructured":"Lomonaco R, Chen J, Cusi K. An endocrine perspective of nonalcoholic fatty liver disease (NAFLD). Ther Adv Endocrinol Metabol 2011;2:211\u2013225","DOI":"10.1177\/2042018811419157"},{"key":"9733_CR5","doi-asserted-by":"crossref","unstructured":"Lonardo A, Loria P, Adinolfi LE, Carulli N, Ruggiero G. Hepatitis C and steatosis: a reappraisal. J Viral Hepat 2006;13(2):73\u201380","DOI":"10.1111\/j.1365-2893.2005.00669.x"},{"key":"9733_CR6","doi-asserted-by":"crossref","unstructured":"Mili\u0107 S, Luli\u0107 D, \u0160timac D. Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations. World J Gastroenterol 2014;20(28):9330\u20139337.","DOI":"10.3748\/wjg.v20.i28.9330"},{"key":"9733_CR7","doi-asserted-by":"crossref","unstructured":"Ampuero J, Romero-G\u00f3mez M, Reddy KR. Review article: HCV genotype 3\u2014the new treatment challenge. Aliment Pharmacol Ther 2014;39(7):686\u2013698","DOI":"10.1111\/apt.12646"},{"key":"9733_CR8","doi-asserted-by":"crossref","unstructured":"Jhaveri R, McHutchison J, Patel K, Qiang G, Diehl AM. Specific polymorphisms in hepatitis C virus genotype 3 core protein associated with intracellular lipid accumulation. J Infect Dis 2008;197:283\u2013291","DOI":"10.1086\/524846"},{"key":"9733_CR9","doi-asserted-by":"crossref","unstructured":"Rubbia-Brandt L, Quadri R, Abid K, Giostra E, Mal\u00e9 PJ, Mentha G, et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 2000;33:106\u2013115","DOI":"10.1016\/S0168-8278(00)80166-X"},{"key":"9733_CR10","doi-asserted-by":"crossref","unstructured":"Nkontchou G, Ziol M, Aout M, Lhabadie M, Baazia Y, Mahmoudi A et al. HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis. J Viral Hepat 2011; 18: e516\u2013e522","DOI":"10.1111\/j.1365-2893.2011.01441.x"},{"key":"9733_CR11","doi-asserted-by":"crossref","unstructured":"Gale M Jr, Foy EM. Evasion of intracellular host defence by hepatitis C virus. Nature 2005; 436: 939\u2013945","DOI":"10.1038\/nature04078"},{"issue":"Suppl 2","key":"9733_CR12","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1478-3231.2008.01950.x","volume":"29","author":"F Negro","year":"2009","unstructured":"Negro F, Sanyal AJ. Hepatitis C virus, steatosis and lipid abnormalities: clinical and pathogenic data. Liver Int 2009;29(Suppl 2):26\u201337","journal-title":"Liver Int"},{"key":"9733_CR13","doi-asserted-by":"crossref","unstructured":"Rosen HR. Emerging concepts in immunity to hepatitis C virus infection. J Clin Invest 2013;123(10):4121\u20134130","DOI":"10.1172\/JCI67714"},{"key":"9733_CR14","doi-asserted-by":"crossref","unstructured":"Lau DT, Negash A, Chen J, Crochet N, Sinha M, Zhang Y, et al. Innate immune tolerance and the role of kupffer cells in differential responses to interferon therapy among patients with HCV genotype 1 infection. Gastroenterology 2013; 144(2): 402\u2013413","DOI":"10.1053\/j.gastro.2012.10.044"},{"key":"9733_CR15","doi-asserted-by":"crossref","unstructured":"Feld JJ, Nanda S, Huang Y, Chen W, Cam M, Pusek SN, et al. Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. Hepatology 2007;46(5):1548\u20131563","DOI":"10.1002\/hep.21853"},{"key":"9733_CR16","doi-asserted-by":"crossref","unstructured":"Felmlee DJ, Hafirassou ML, Lefevre M, Baumert TF, Schuster C. Hepatitis C virus, cholesterol and lipoproteins impact for the viral life cycle and pathogenesis of liver disease. Viruses 2013;5:1292\u20131324","DOI":"10.3390\/v5051292"},{"key":"9733_CR17","doi-asserted-by":"crossref","unstructured":"Negro F. Hepatitis C in 2013: HCV causes systemic disorders that can be cured. Nat Rev Gastroenterol Hepatol 2014;11:77\u201378","DOI":"10.1038\/nrgastro.2013.222"},{"key":"9733_CR18","doi-asserted-by":"crossref","unstructured":"Bartenschlager R, Lohmann V, Penin F. The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. Nat Rev Microbiol 2013;11(482\u2013496):13","DOI":"10.1038\/nrmicro3046"},{"key":"9733_CR19","doi-asserted-by":"crossref","unstructured":"Miyanari Y, Atsuzawa K, Usuda N, Watashi K, Hishiki T, Zayas M, et al. The lipid droplet is an important organelle for hepatitis C virus production. Nat Cell Biol 2007;9:1089\u20131097","DOI":"10.1038\/ncb1631"},{"key":"9733_CR20","doi-asserted-by":"crossref","unstructured":"Katsounas A, Hubbard JJ, Wang CH, Zhang X, Dou D, Shivakumar B, et.al. High interferon-stimulated gene ISG-15 expression affects HCV treatment outcome in patients co-infected with HIV and HCV. J Med Virol 2013; 85(6): 959\u2013993","DOI":"10.1002\/jmv.23576"},{"key":"9733_CR21","doi-asserted-by":"crossref","unstructured":"Onomoto K, Morimoto S, Kawaguchi T, Toyoda H, Tanaka M, Kuroda M, Uno K, Kumada T, Matsuda F, Shimotohno K, Fujita T, Murakami Y. Dysregulation of IFN system can lead to poor response to pegylated interferon and ribavirin therapy in chronic hepatitis C. PLoS ONE 2011;6(5):e19799","DOI":"10.1371\/journal.pone.0019799"},{"key":"9733_CR22","doi-asserted-by":"crossref","unstructured":"Larrubia JR, Benito-Mart\u00ednez S, Calvino M, Sanz-de-Villalobos E, Parra-Cid T. Role of chemokines and their receptors in viral persistence and liver damage during chronic hepatitis C virus infection. World J Gastroenterol 2008;14(47):7149\u20137159","DOI":"10.3748\/wjg.14.7149"},{"key":"9733_CR23","doi-asserted-by":"crossref","unstructured":"St\u00e4ttermayer AF, Scherzer T, Beinhardt S, Rutter K, Hofer H, Ferenci P. Review article: genetic factors that modify the outcome of viral hepatitis. Aliment Pharmacol Ther 2014;39(10):1059\u20131070","DOI":"10.1111\/apt.12717"},{"key":"9733_CR24","doi-asserted-by":"crossref","unstructured":"Naggie S, Osinusi A, Katsounas A, Lempicki R, Herrmann E, Thompson AJ, et al. Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response. Hepatology 2012;56(2):444\u2013454","DOI":"10.1002\/hep.25647"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-016-9733-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12072-016-9733-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-016-9733-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-016-9733-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T15:03:59Z","timestamp":1748963039000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12072-016-9733-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,18]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["9733"],"URL":"https:\/\/doi.org\/10.1007\/s12072-016-9733-6","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,18]]}}}